🇺🇸 FDA
Pipeline program

γδT Cell infusion agent

PG-γδT-001

Phase 1 small_molecule active

Quick answer

γδT Cell infusion agent for Leukemia, B-cell is a Phase 1 program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
First Tracks Biotherapeutics
Indication
Leukemia, B-cell
Phase
Phase 1
Modality
small_molecule
Status
active

Clinical trials